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Article
The potential role of blood biomarkers
in patients with ischemic stroke:
An expert opinion
Mira Katan1 and Mitchell SV Elkind2
Abstract
Blood biomarkers are increasingly beginning to play a role in the diagnosis, management, and prognostication of patients
with acute ischemic stroke. While imaging biomarkers have played the largest role in determining acute therapies, blood-
based biomarkers may have important contributions to make in settings where imaging is not readily available, or when
making predictions about future complications and recurrent stroke. Though more research in large, diverse patient
populations are needed before blood-based biomarkers become widely accepted for stroke management, preliminary
reports suggest their value in several settings and the use of biomarkers is gaining traction. This article discusses the role of
several selected readily available protein biomarkers in stroke diagnosis, acute management decisions, and prognosis.
Protein biomarkers were primarily selected based on the fact that they have been evaluated in cohort studies and ideally
that they have been validated by independent groups.
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What is a biomarker?
In 1998, a working group at the United States National
Institutes of Health defined a biomarker as a biological
marker that is objectively measured and evaluated as an
indicator of normal biological processes, pathological pro-
cesses, or pharmacological responses to therapeutic inter-
ventions.1 The term biomarker is thus a generic term that
includes physiological parameters, clinical images, and the
results of testing of tissue samples, including blood. Surro-
gate biomarkers are a subset of biomarkers that are used in
place of clinical outcomes in trials or other studies. Vali-
dated surrogate biomarkers, moreover, include the very
limited number of biomarkers for which the evidence of
association with clinical disease is considered so strong that
the biomarker can substitute for a clinical outcome (such as
functional outcome, recurrent stroke, or death) in a clinical
trial, and be used to make a determination of approval by a
regulatory agency. Examples of validated surrogate bio-
markers are generally limited to physiological parameters
such as blood pressure or laboratory test results (e.g. viral
load) in selected diseases such as human immunodefi-
ciency virus infection. This article focuses on blood protein
biomarkers; at present, no blood biomarkers can be consid-
ered validated surrogates in the stroke field.
In the setting of acute ischemic stroke, a blood biomar-
ker can be any quantifiable entity that assesses the mani-
festation of a stroke-related process. The most successful
implementation of stroke biomarkers is in areas where
information from traditional clinical sources, such as the
patient history or clinical examination, is limited. For
example, markers can be used to identify patients that may
benefit most from acute interventions, reveal stroke etiol-
ogy, estimate the risk of short-term complications or unfa-
vorable long-term outcomes, and monitor treatment
efficacy of secondary prevention.2 To address these
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questions, stroke-related biomarkers may reflect diverse
processes immediately preceding stroke or processes dur-
ing and after stroke.
An effective biomarker should allow precise measure-
ments with a fast turnaround time at reasonable cost.3
Moreover, it should provide information that is not already
available from careful clinical assessment, and its perfor-
mance should be at least complementary to other available
tests.3 Ideally, a biomarker should assist decision-making
and ultimately enhance clinical care.
A biomarker does not necessarily need to be sensitive and
specific at the same time, depending on the clinical question
being addressed. It might, for example, only be used to rule
in a disease (specificity) or rule it out (sensitivity).
To discuss the entirety of different candidate biomarkers
that have been studied in stroke patients so far would go
well beyond the scope of this article. We aim rather to
discuss several interesting candidate protein biomarkers for
specific clinical questions that, in our opinion, elucidate
concepts of potential implementation in stroke patients.
Diagnostic stroke biomarkers
In the present era of generally available diagnostic neuroi-
maging, the diagnosis of ischemic stroke is often straight-
forward. In scenarios in which imaging resources are
limited, however, blood-based biomarkers for the diagnosis
of stroke may be of value, much like cardiac troponin is
used to diagnose cardiac ischemic injury. Also, in prehos-
pital settings a reliable diagnostic biomarker could be help-
ful to facilitate early diagnosis and triage patients
appropriately, since history and exam alone cannot provide
a reliable diagnosis.
Among the most important features of a diagnostic bio-
marker are the ability to determine the presence of a stroke
and to differentiate between ischemic and hemorrhagic
stroke subtypes, due to diametrically opposed treatments
offered for each (e.g. treatment with tissue-type plasmi-
nogen activator (tPA) for ischemic stroke versus poten-
tial reversal of novel oral anticoagulants in hemorrhagic
stroke). Distinguishing ischemic stroke from stroke
“mimics,” such as migraine, seizure, or hypoglycemia,
is also important, although there is evidence that treating
mimics with tPA is relatively safe.4 Thus, the essential
measure of a biomarker’s utility is whether it can be
used to distinguish an ischemic brain lesion from hemor-
rhagic lesions.
General brain injury biomarkers, such as neuron-
specific enolase, are limited in their capacity to serve as
markers for ischemic stroke because they are not specific to
ischemic stroke, and many disease processes can damage
brain tissue. In addition, several brain injury markers are
not exclusively released by brain tissue but can also be
released by extra-cerebral tissues. Another complicating
factor is the fact that the blood–brain barrier restricts the
release of these biomarkers into the systemic circulation in
the early phase after the injury.
Despite these limitations, several individual biomarkers
of brain injury have been evaluated concerning their ability
to discern ischemic from hemorrhagic stroke and other
mimics.5 The most commonly studied protein markers of
stroke diagnosis are summarized in Table 1. Glial fibrillary
acidic protein (GFAP) is one of the most promising and
consistent markers. In a multicenter study, GFAP was able
to distinguish hemorrhagic from ischemic stroke in the first
6 h after symptom onset with a high sensitivity (81%) and
specificity (95%) for the diagnosis of primary hemorrhagic
stroke (thus excluding ischemic stroke).11 A recent inde-
pendent study was able to confirm these results: A cutoff
value of 0.43 ng/mL was the optimal threshold for the
differentiation between intracerebral hemorrhage and
ischemic stroke, with a sensitivity of 91% and a specificity
of 97%.12 An outstanding question, however, is whether
these numbers translate into an acceptable distinction in
Table 1. Selection of protein blood biomarkers in stroke diagnosis.
Brain tissue injury markers Inflammatory markers
Hemostatic
markers Miscellaneous markers
Single protein
markers
S100B, GFAP, NSE, NMDA-R
Ab, MBP, NFls, BNGF
CRP, IL-6, IL-1b, TNF-α, cFn,
VCAM 1, MMP9, ApoC-I
ApoC-III, chimerin II
DD, vWF,
fibrinogen,
PAI-1,
BNP or NT-proBNP, PARK 7,
NDKA, H-FABP, retinol-binding
protein 4, secretatogin,
caspase-3, endostatin
Protein marker-
based panels
Caspase 3, d-dimer, sRAGE, chimerin II, secretagogin and MMP-96
BNGF, MCP-1, MMP-9, S100-B, vWF7
BNP, DD, MMP9, S100B8
Eotaxin, MCP-1, S100 A12, MMP-4, prolactin9
sRAGE, S100B10
ApoC I/III: apolipoprotein-C I/III; BNGF: B-type neurotrophic growth factor; cFN: cellular fibronectin; CRP: C-reactive protein; DD: D-dimer; GFAP:
glial fibrillary acidic protein; H-FABP: heart fatty acid binding protein; IL-1b: interleukin-1b; IL-6: interleukin-6; MBP: myelin basic protein; MCP-1:
monocyte chemotactic protein-1; MMP-9: matrix metalloproteinases-9; NDKA: nucleoside diphosphate kinase A; Nfl: neurofilament; NMDA-R Ab:
N-methyl-D-aspartate receptor antibody; NSE: neuron-specific enolase; NT-proBNP: N-terminal-pro B-type natriuretic peptide; PAI-1: plasminogen
activator inhibitor 1; RBP-4: retinol-binding protein 4; S100-B: calcium binding protein-beta; sRAGE: soluble receptor for advanced glycation end
products; TNF-α: tumor necrosis factor-α; VCAM1: vascular cell adhesion molecule 1; vWF: von Willebrand factor.
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the clinical setting in which a choice to use tPA must
be made.
The addition of N-terminal brain natriuretic peptide
(NT-proBNP) might add incremental value for the dif-
ferentiation of hemorrhagic versus ischemic strokes. In a
recent study including more than 1000 patients into the
derivation cohort and more than 700 in an independent
validation cohort, among 21 prespecified markers, only
NT-proBNP was independently associated with the diag-
nosis of ischemic stroke when compared to patients with
hemorrhagic stroke.13 Besides NT-proBNP, only endo-
statin and D-dimer were among those markers with
potential for integration into a multimarker panel distin-
guishing stroke subtypes.13 Interestingly, all these mar-
kers are not brain-specific markers but rather markers
associated with the underlying cause of brain ischemia
(i.e. etiological markers).
In a preclinical setting (e.g. ambulance), measuring
GFAP, NT-proBNP, and potentially other markers with
a point-of-care tool could eventually be used to guide
ultra-early antihypertensive treatments or rapid reversal
of anticoagulation in hemorrhagic stroke patients. In com-
bination with other biomarkers, they might even guide
decisions for intravenous tPA treatment where no imaging
modalities are available. Currently, however, we are not
able to discriminate well enough between stroke subtypes
to base most therapeutic decisions on biomarker levels,
whether single markers or multimarker panels, and more
research is needed.
Prognostic biomarkers after stroke
One of the first questions asked by relatives and patients
admitted to the hospital with an acute ischemic stroke
relates to their prognosis. Accurate prognosis is not only
relevant for patient and relatives but also for physicians to
optimize care and allocation of health-care resources. Out-
come after ischemic stroke depends on a complex interac-
tion of multiple factors, all of which contribute to break the
balance either toward a favorable or unfavorable out-
come.14 Several clinical scales have been developed to
predict outcome in stroke patients. One of the best vali-
dated and leanest scores contains only two variables—age
and the National Institutes of Health Stroke Scale (NIHSS).
The score achieved an area under the curve of 0.81 for
disability and of 0.71 for mortality 3 months after stroke.15
Blood markers may increase the prognostic accuracy of
scores, keeping them still quite simple and objective at the
same time.
Many candidate markers have been studied, and higher
levels of biomarkers of most pathophysiological processes
involved with stroke are associated with worse outcome
after stroke.16 Even though some markers (e.g. interleukin
6 and NT-pro BNP) do have an independent association
with poor outcome, it does not appear that they make very
much difference to the accuracy of prediction of poor
outcome over and above these more simply measured clin-
ical variables.17
One exception may be copeptin, a neuroendocrine mar-
ker. Copeptin is released by the hypothalamus in equimolar
concentrations to vasopressin, an active hormone involved
in the body’s response to sympathetic activation and thus
stress. Copeptin can therefore serve as a blood biomarker of
stress, and its levels have been correlated with the individ-
ual stress level in various settings.18 In a derivation cohort
of 362 ischemic stroke patients, the combination of copep-
tin concentrations with the NIHSS predicted both func-
tional outcome and mortality within 90 days significantly
better than the clinical scale or the biomarker alone. The
estimated net reclassification improvement for functional
outcome was 40% and for mortality 50%, suggesting clini-
cally relevant incremental value for risk stratification.19
These results were confirmed in several recent independent
validation cohorts.20–22
Probably even more important than prognosis of overall
outcome is an accurate prediction of specific complications
after stroke, which then can be directly addressed to
improve outcome. Common complications that could be
targeted include poststroke pneumonia, seizures, malignant
cerebral edema, and hemorrhagic transformation, including
in particular symptomatic intracerebral hemorrhage. Few
markers have been stringently studied and independently
validated in more than one cohort for the prediction of these
clinical endpoints, and there is still much work needed.
Matrix metalloproteinase-9 (MMP-9), however, is a
promising candidate for the prediction of hemorrhagic
transformation and S100B (calcium binding protein-beta)
for the development of malignant edema. MMP-9 plasma
levels determined prior to thrombolytic therapy have been
found to predict hemorrhagic transformation (HT) after
intravenous thrombolysis. A graded response was found
between pretreatment MMP-9 blood concentrations and
the degree of HT.23,24 Moreover, MMP-9 was also an
independent predictor of HT in non-thrombolyzed
ischemic stroke patients.25
A 12-h S100B value of >0.35 g/L predicted a malignant
infarction with a sensitivity of 75% and a specificity of
80%. A 24-h S100B value of >1.03 g/L provided a sensi-
tivity of 94% and a specificity of 83%, though these results
have not been independently validated in a larger cohort.26
Accurate markers of stroke recurrence also would be
very helpful for efficient triage in the emergency setting,
especially in patients with transient ischemic attacks
(TIAs). So far there have been only a few markers exten-
sively evaluated for this purpose, among them are
C-reactive protein (CRP), lipoprotein-associated phospho-
lipase A2 (LpPLA2), and copeptin. CRP has been associ-
ated mostly with vascular disease incidence, but some
studies also report an association with stroke recurrence,27,28
while others do not.29,30 Because CRP is an acute phase
reactant, and its concentrations increase in proportion to
the severity of the stroke itself as well as the burden of the
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patient’s comorbidities, CRP tends to correlate more with
mortality than stroke risk. CRP has been shown to be
helpful for recurrence risk prediction among lacunar
stroke patients,31 however, in whom the burden of brain
injury and consequent inflammatory reaction is lower.
Another inflammatory marker, Lp-PLA2, metabolizes
low-density lipoprotein (LDL) to form free fatty acids and
other pro-inflammatory moieties. LpPLA2 was indepen-
dently associated with mortality but also with risk of
recurrent stroke in independent studies.30,32,33 Two rando-
mized trials of darapladib, a novel inhibitor of Lp-PLA2,
have been conducted among patients with cardiovascular
disease, but they failed to show that the drug prevents
stroke, suggesting that LpPLA2 may not have a direct
causal link with stroke risk.34,35
Copeptin concentrations have been demonstrated to pre-
dict re-events after TIA and stroke, with an incremental
value over the usually used clinical risk stratification mod-
els, in at least three independent studies.36–38 Recently, a
promising panel of three serum biomarkers—osteopontin,
neopterin, and myeloperoxidase—was independently asso-
ciated with the risk of recurrent stroke, and improved risk
classification when added to a clinical risk algorithm with a
continuous net reclassification improvement of 29.1%.39
These results are promising. The next step would be to
compare (ideally in a randomized trial) the clinical gold-
standard algorithm for risk stratification including
biomarker measurements to the gold standard without the
biomarker measurements.
Etiologic stroke biomarkers
Ischemic stroke is a heterogeneous disease. Etiologic clas-
sification is specifically important because prognosis, risk
of recurrence, and management options differ greatly
between etiological subtypes. Considering that up to 30%
of stroke patients cannot be classified into a specific sub-
type,40 the ability to improve etiological classification to
direct prevention methods at the underlying mechanism
could be of great value.
The Trial of Organon in Acute Stroke Therapy
(TOAST)41 classification system is the most commonly
used in patients with ischemic stroke. This system classifies
ischemic strokes as due to large-vessel atherosclerosis,
cardioembolic source, small vessel disease, other
“determined” causes, and stroke of “undetermined” etiol-
ogy. The last mentioned category comprises also those
patients without known cause due to incomplete evaluation
or due to the occurrence of multiple competing causes.
Most studies to assess etiological biomarkers have used the
TOAST classification system because secondary preven-
tion studies have usually used this system to select patients.
The beginning of the pathophysiological process in
ischemic strokes due to large artery atherosclerosis is
mainly of an inflammatory nature. Small vessel disease can
be attributed to several patho-mechanisms, including
similar mechanisms as in large vessel atherosclerosis, but
also local fibrinoid necrosis, lipohyalinosis, microather-
oma, microaneurysms, and segmental arterial disorganiza-
tion.42 As a consequence, blood biomarkers indicating
inflammatory vessel processes might be useful etiological
biomarker candidates for both large and small vessel dis-
eases. CRP, interleukin-6, interleukin-1b, and tumor necro-
sis factor alpha all have been implicated in small vessel
stroke as well as large vessel strokes.43–45 In the acute
phase after stroke, however, they are also elevated in car-
dioembolic stroke patients.46 Moreover, intracellular adhe-
sion molecule-1 (ICAM-1),47–49 soluble Receptor for
Advanced Glycation Endproducts (sRAGE),50 fibrino-
gen,51 P-selectin,52 and adiponectin53 have also been asso-
ciated with large vessel disease. LP-PLA2 was found to be
independently associated with ischemic stroke due to large
artery atherosclerosis in White non-Hispanic men.54 In
another study,55 patients suffering from TIA due to large
artery atherosclerosis had higher LpPLA2 activity com-
pared to patients suffering from TIA due to non-large artery
atherosclerosis.
In the case of cardioembolic stroke, single markers or
multimarker biomarker panels indicative of underlying car-
diac disease may be most helpful. Among the many eval-
uated markers, the natriuretic peptides have been studied
extensively and the evidence level for these protein mar-
kers is currently the highest. Several studies have con-
firmed that natriuretic peptides, mainly NT-proBNP55,56
and mid-regional atrial natriuretic peptide (MRproANP),57
are able to identify primarily cardioembolic stroke subtypes
as well as stroke risk.58 In addition, higher NT-proBNP
levels were associated with a relative benefit of warfarin
compared with aspirin for prevention of recurrent stroke.59
Based on these findings, a clinical trial in the United States
is testing whether the use of biomarkers, including serum
NT-proBNP, among patients with unexplained stroke can
be used to select patients with atrial dysfunction (“atrial
cardiopathy”) for treatment with anticoagulant therapy, just
as patients with atrial fibrillation have been treated with
anticoagulants for many years (http://clinicaltrials.gov
identifier NCT03192215).
Conclusion
The majority of current biomarker studies in vascular neu-
rology have not reached the evidence level to draw final
conclusions. However, with over 250,000 proteins, in addi-
tion to 20,000 coding genes and an ever increasing number
of non-coding genes, metabolites, and lipids, it is important
to recognize that the molecular features of human stroke
are still being determined and evaluated.60 Of the many
molecules, those with optimal biomarker potential in stroke
likely remain at least partly unknown.60 Efforts to define
the molecular fingerprints of stroke are ongoing. However,
besides focusing on an improved identification of novel
markers and most likely marker panels, future efforts
4 Clinical & Translational Neuroscience
should also include improvement in validation of interest-
ing candidates, in taking the most promising markers to the
next step, and producing evidence of improvement in
patient management and ultimately outcome based on
blood biomarker guidance.
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